Judging by 28 different metrics, Vermont offers the highest-quality and most cost-efficient care for children, according to a new study from personal finance website WalletHub, while Nevada struggles with limited access to care and poor oral health among those under the age of 18. 

Clinicians have another chance to influence how the Medicare Access and CHIP Reauthorization Act (MACRA) measures meaningful use, as CMS will be taking suggestions on new measures through June 30.

The study will examine the immuno-genetic underpinnings of the respiratory infection caused by inhalation of fungal spores—known as Coccidioides—endemic to soils of the U.S. Southwest. 

The growing demand for quality healthcare has revolutionised the health monitoring space through use of wearable and ingestible sensors. Emphasis on preventive health has lead to the development of prognostic sensors for applications in medical space. This has lead to the shift of healthcare business model from a diagnostic one to more prognostic and preventive health and wellness. Sensor adoption is crucial to this evolution, facilitating advanced diagnostics, treatment, and patient monitoring. Wearable and implantable biosensors will emerge as the key enablers for device innovation, as well as will be commercialised as prognostic tools.

Fears that repealing the Affordable Care Act (ACA) would reverse years of efforts to lower cost and improve quality are “overblown,” according to health policy fellows from a conservative think tank writing in Health Affairs.

Falls by elderly individuals oftentimes result in hospitalization—and a lack of methods to predict balance impairment doesn’t help. A study, published in Scientific Reports, found the use of virtual reality (VR) can identify imbalance in patients and prevent falls.

Providers who want to take advantage of value-based reimbursements and avoid MACRA penalties in 2018 must act fast – Caravan Health, the market leader in Accountable Care Organizations (ACOs), has extended its deadline for consideration in a 2018 ACO to April 30, 2017.

Building on their recent research focusing on a peptide, pNaKtide, designed to block the oxidant amplifying function of the cellular sodium-potassium pump, researchers at Marshall University Joan C. Edwards School of Medicine have successfully demonstrated that pNaKtide can attenuate the development of experimental nonalcoholic fatty liver disease (NAFLD) and atherosclerosis.